医学
曲菌病
丹麦语
内科学
过敏性支气管肺曲菌病
入射(几何)
风险因素
回顾性队列研究
烟曲霉
皮质类固醇
免疫抑制
比率
逻辑回归
呼吸道疾病
慢性阻塞性肺病
病例对照研究
肺
真菌病
混淆
重症监护医学
外科
肺活量测定
药方
优势比
强的松
相对风险
吸入性皮质类固醇
流行病学
作者
Alexander Svorre Jordan,Louise Lindhardt Toennesen,Bård-Emil Vang Gundersen,Jens‐Ulrik Stæhr Jensen
出处
期刊:Thorax
[BMJ]
日期:2026-07-31
卷期号:: thorax-2026
被引量:1
标识
DOI:10.1136/thorax-2026-225007
摘要
BACKGROUND: sp. Chronic lung diseases and immunosuppression are known risk factors, but data on the impact of corticosteroids and their route of administration are limited. METHODS: To evaluate the association between corticosteroid use and pulmonary aspergillosis, we conducted a retrospective case-control study in all Danish citizens who redeemed at least one prescription for inhaled medicine between 1994 and 2025. We identified 1351 patients with aspergillosis other than allergic bronchopulmonary aspergillosis (ABPA) and matched them to controls (1:5) by age, sex and calendar year using risk set sampling. Conditional logistic regression was used to estimate adjusted incidence rate ratios (aIRRs) for chronic pulmonary aspergillosis (CPA) and invasive pulmonary aspergillosis (IPA) across dose categories and 90-day exposure windows. The use of risk-set sampling allowed for estimating IRRs. RESULTS: Inhaled corticosteroids were associated with non-ABPA aspergillosis in a dose-dependent manner (aIRR 1.7 (95% CI 1.3 to 2.2) for use ≤640 µg/day, aIRR 2.8 (2.2 to 3.6) for use >640 µg/day, compared with no use) but only associated with IPA for higher doses. Oral corticosteroids (OCS) were similarly associated with non-ABPA aspergillosis (aIRR 3.0 (95% CI 2.2 to 4.1) for OCS use ≤5.6 mg/day, aIRR 4.0 (2.9 to 5.4) for OCS use >5.6 mg/day, both compared with no use), affecting both CPA and IPA. The risk decreased with increasing time since exposure. CONCLUSION: Our results demonstrate a strong and seemingly dose-dependent association between both systemic and inhaled corticosteroid use and aspergillosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI